Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
Refine your Search
|
Title
|
Publication Date
|
Price
|
Relevance
|
|
Benign Prostatic Hyperplasia Therapy Area Pipeline Report
|
Mar 2011 |
£945 |
100% |
Benign Prostatic Hyperplasia (BPH) Therapeutics
Pipeline Assessment and Market Forecasts to 2018
|
Oct 2011 |
£2,215 |
99% |
Dutasteride: Core Country Coverage
Pipeline Selector
|
Jun 2011 |
£250 |
62% |
Cardiovascular and Interventional Radiological Society of Europe
Conference Review and Analysis
|
Nov 2010 |
£630 |
60% |
Dutasteride - Key patent, SPC, and data exclusivity expiry (7 country coverage)
Pipeline Selector Core
|
Jun 2011 |
£310 |
58% |
Dutasteride - Key patent, SPC, and data exclusivity expiry (44 countries coverage)
Pipeline Selector Extended
|
Jun 2011 |
£705 |
55% |
|
Astellas Pharma Inc.: PharmaVitae Profile
|
Jun 2010 |
£3,605 |
54% |
Alfuzosin - Key patent, SPC, and data exclusivity expiry (7 country coverage)
Pipeline Selector Core
|
Jun 2011 |
£310 |
54% |
Finasteride - Key patent, SPC, and data exclusivity expiry (7 country coverage)
Pipeline Selector Core
|
Jun 2011 |
£310 |
54% |
Tamsulosin - Key patent, SPC, and data exclusivity expiry (7 country coverage)
Pipeline Selector Core
|
Jun 2011 |
£310 |
54% |
Finasteride - Key patent, SPC, and data exclusivity expiry (44 countries coverage)
Pipeline Selector Extended
|
Jun 2011 |
£705 |
51% |
Alfuzosin - Key patent, SPC, and data exclusivity expiry (44 countries coverage)
Pipeline Selector Extended
|
Jun 2011 |
£705 |
51% |
Tamsulosin - Key patent, SPC, and data exclusivity expiry (44 countries coverage)
Pipeline Selector Extended
|
Jun 2011 |
£705 |
51% |
